Review paper
Neoadjuvant immunotherapy in melanoma - the new frontier
Abstract
Neoadjuvant immunotherapy is gathering pace, particularly in melanoma. A recent study of pembrolizumab and HDI not only further supports the safety and activity of neoadjuvant anti–PD-1 based immunotherapy but also highlights neoadjuvant therapy as a solid platform for drug development that is likely to become a standard-of-care in the near future. null See related article by Najjar et al., p....
Paper Details
Title
Neoadjuvant immunotherapy in melanoma - the new frontier
Published Date
Jun 3, 2021
Journal
Volume
27
Issue
15
Pages
4133 - 4135
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History